Rucaparib or Physician's Choice in Metastatic Prostate Cancer
Por um escritor misterioso
Descrição
Advanced Prostate Cancer: AUA/SUO Guideline - American Urological Association
Platinum-based chemotherapy in metastatic prostate cancer: what possibilities?
Rucaparib or Physician's Choice in Metastatic Prostate Cancer
Rucaparib provides better survival than usual care in metastatic prostate cancer - Hospital Pharmacy EuropeHospital Pharmacy Europe
Advanced Prostate Cancer: Treatment Advances and Future Directions: Trends in Cancer
PDF] Trial of rucaparib in prostate indications 3 (TRITON3): An international, multicenter, randomized, open-label phase 3 study of rucaparib vs physician's choice of therapy for patients (Pts) with metastatic castration-resistant prostate cancer (
Real-World Treatment Patterns and Overall Survival of Patients with Metastatic Castration-Resistant Prostate Cancer in the US Prior to PARP Inhibitors
PARP inhibitors, rucaparib (Rubraca) and olaparib (Lynparza) receive FDA approval for metastatic prostate cancer
FDA Approves Olaparib, Rucaparib to Treat Prostate Cancer - NCI
Practical considerations for optimising homologous recombination repair mutation testing in patients with metastatic prostate cancer - Gonzalez - 2021 - The Journal of Pathology: Clinical Research - Wiley Online Library
Guidelines for Management of treating Rucaparib
Prostate cancer and PARP inhibitors: progress and challenges, Journal of Hematology & Oncology
de
por adulto (o preço varia de acordo com o tamanho do grupo)
